METHODS FOR TREATING CHRONIC RHINOSINUSITIS
A method of delivering a substance, such as fluticasone propionate, a nasal steroid and/or carbon dioxide gas, to the nasal cavity of a subject, in particular for the treatment of sinus and/or nasal inflammatory diseases, for example, chronic rhinosinusitis with or without nasal polyps, to reduce sinus inflammation, reduce sinus opacification, and/or improve associated symptoms.
1 . A method for treating chronic rhinosinusitis or chronic sinusitis in a subject in need thereof, comprising bi-directionally delivering, via an exhalation delivery device, a dose of about 186 μg of fluticasone propionate BID to the upper posterior region of a nasal airway in the subject.
2 . A method for treating chronic rhinosinusitis or chronic sinusitis in a subject in need thereof, comprising bi-directionally delivering, via an exhalation delivery device, a dose of about 372 μg of fluticasone propionate BID to the upper posterior region of a nasal airway in the subject.
3 . The method of claim 1 , further comprising inserting a nosepiece into the subject's nasal passage and a mouthpiece that is gripped by the subject's lips.
4 . The method of claim 2 , further comprising inserting a nosepiece into the subject's nasal passage and a mouthpiece that is gripped by the subject's lips.
5 . The method of claim 3 , further comprising exhaling through the mouthpiece, the exhalation breath providing for delivery of a dose of the fluticasone propionate.
6 . The method of claim 4 , further comprising exhaling through the mouthpiece, the exhalation breath providing for delivery of a dose of the fluticasone propionate.
7 . The method of claim 1 , comprising delivering a dose of about 93 μg of fluticasone propionate in each nasal cavity BID.
8 . The method of claim 2 , comprising delivering a dose of about 186 μg of fluticasone propionate in each nasal cavity BID.
9 . The method of claim 1 , wherein delivering the fluticasone propionate to the subject's upper posterior region of a nasal passageway results in a reduction in inflammation and/or a reduction in sinus opacification.
10 . The method of claim 2 , wherein delivering the fluticasone propionate to the subject's upper posterior region of a nasal passageway results in a reduction in inflammation and/or a reduction in sinus opacification.
11 . The method of claim 9 , wherein delivering the fluticasone propionate to the subject's upper posterior region of a nasal passageway further results in the improvement of one or more of facial pain or pressure, nasal congestion/blockage, rhinorrhea, and sense of smell.
12 . The method of claim 10 , wherein delivering the fluticasone propionate to the subject's upper posterior region of a nasal passageway further results in the improvement of one or more of facial pain or pressure, nasal congestion/blockage, rhinorrhea, and sense of smell.
13 . The method of claim 1 , wherein delivering the fluticasone propionate to the subject's upper posterior region of a nasal passageway results in a reduction of incidence of acute exacerbations of chronic rhinosinusitis (AECRS).
14 . The method of claim 2 , wherein delivering the fluticasone propionate to the subject's upper posterior region of a nasal passageway results in a reduction of incidence of acute exacerbations of chronic rhinosinusitis (AECRS).
15 . The method of claim 1 , wherein the fluticasone propionate is administered for about 24 weeks.
16 . The method of claim 2 , wherein the fluticasone propionate is administered for about 24 weeks.